UPDATE: Allergan (AGN) Increases Quarterly Dividend 2.86% to $0.72; 1.8% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
Go back to UPDATE: Allergan (AGN) Increases Quarterly Dividend 2.86% to $0.72; 1.8% Yield
February 7, 2018 9:11 AM EST
BofA/Merrill Lynch raised its price target on Allergen (NYSE: AGN) to $215.00 (from $208.00) while maintaining a Buy rating.
...
More
February 7, 2018 8:12 AM EST
Credit Suisse raised its price target on Allergen (NYSE: AGN) to $215.00 (from $214.00) while maintaining a Outperform rating.
...
More
February 7, 2018 8:11 AM EST
Deutsche Bank analyst, Gregg Gilbert, reiterated his Buy rating on shares of Allergen (NYSE: AGN) and raised the price target to $215 from $212 after the company reported solid 4Q results with revenue and EPS above and consensus driven by strong growth for the aesthetics business. The... More
February 7, 2018 7:39 AM EST
Leerink Partners raised its price target on Allergen (NYSE: AGN) to $242.00 (from $237.00) while maintaining a Outperform rating.
Analyst Seamus Fernandez commented, "Following Tuesdays call we are incrementally more confident in the approvability of ubrogepant for acute migraine and AGNs ability to execute on 2018... More
February 7, 2018 6:41 AM EST
Piper Jaffray lowered its price target on Allergen (NYSE: AGN) to $171.00 (from $176.00) while maintaining a Neutral rating.
...
More
February 7, 2018 6:20 AM EST
Citi lowered its price target on Allergen (NYSE: AGN) to $220.00 (from $240.00) while maintaining a Buy rating.
...
More
February 7, 2018 6:00 AM EST
Deutsche Bank lowered its price target on Allergen (NYSE: AGN) to $212.00 (from $215.00) while maintaining a Buy rating.
...
More
